ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

idelalisib

Also written as “Idelalisib”, “CAL-101” and “CAL101”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Idiopathic Pulmonary Fibrosis · Primary Myelofibrosis · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Drug pageIdelalisib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 12, 201628 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only260 open or runningphase 4since Apr 12, 2016Jul 1, 2008none ahead
Calluna Pharma ASits history only11 open or runningphase 2since Dec 16, 2024Dec 16, 2024Nov 2026phase 2 · NCT06736990
Eli Lilly11 open or runningphase 4since Oct 16, 2025Oct 16, 2025May 2030phase 4 · NCT07218341

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2025First study: phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT07218341 · 150 planned · United States, Australia, Austria and more

Ahead

  1. May 2030Primary completion: phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07218341

TargetBeta

PIK3CD →read by rule
“An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) ”NCIt, by rule
“PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
duvelisibruleSecuraBiophase 326
leniolisibrulePharming Groupphase 39
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24
roginolisibruleioncturaphase 24

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more4RecruitingMay 2030150

How it is read

Names in the registry

  • “Idelalisib”, 24 entries
  • “CAL-101”, 2 entries
  • “CAL101”, 1 entry
  • “GS-1101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.